Bespoke rare disease pharmaceutical services
An end-to-end solution for your specific needs in three steps
Step 1: Finding the right patients
Sciensus takes a tailored approach to identifying patients with rare and orphan diseases. Our in-country teams work closely with healthcare professionals to improve early diagnosis. By collaborating with patient organisations, we streamline the patient journey and reduce diagnosis times. Our peer-to-peer education and targeted outreach ensure healthcare providers have the latest insights to connect patients with treatment faster.
Step 2: Ensuring safe & timely patient access
We help pharma companies navigate regulatory pathways and early access programs to provide treatment, even before full commercialisation. We offer specialised supply chain management to ensure medicines reach patients safely, on time, and with minimal disruption, even within complex healthcare systems.
Step 3: Supporting patients through treatment
Our Patient Support Programmes (PSP) provide ongoing digital and in-person care by highly qualified healthcare professionals across Europe. These programs enhance patient outcomes and capture patient and clinician reported outcomes – generating real-world data to inform future treatment strategies.
Sciensus’ rare diseases consulting services
Expanding a rare disease drug into the European market requires expert navigation of regulatory pathways, patient access strategies, and commercialisation challenges. Sciensus provides tailored rare diseases consulting services, helping pharmaceutical companies secure regulatory approvals, implement Expanded Access Programmes, optimise supply chains, and engage with hard-to-reach patient populations. Our end-to-end support makes sure your treatment reaches the right patients – efficiently and compliantly.
Expertise
Scalability
Local access
Multilingual team
Transform market challenges into opportunities
With Sciensus as your rare diseases consulting services partner, you can confidently expand into the European market, ensuring that patients receive life-changing treatments without unnecessary delays.
Ready to bring your rare disease treatment to Europe?
Learn more about our services from our expert team
Our track record in rare disease therapy distribution
With over 30 years of experience collaborating with US biotech companies to offer turnkey solutions for finding and assisting patients in Europe, we are ready to go. At pace.
$ 0
orphan drugs bought and sold per year
0
relationships with healthcare providers
0
units of orphan medicine supplied
Answering your questions
What are the biggest challenges in commercialising rare disease drugs in Europe?
Expanding into the European market involves navigating complex regulations, securing early patient access, optimising supply chains, and patient engagement. Sciensus provides rare diseases consulting services to simplify this process, helping pharmaceutical companies overcome these barriers efficiently.
How does Sciensus help pharma companies find rare disease patients?
We use a customised, data-driven approach that includes strategic collaboration with patient organisations, physician education, real-world data collection, and targeted outreach programmes. By reducing diagnosis times and improving patient identification, we help accelerate access to treatment.
What is an Expanded Access Programme (EAP) and how can Sciensus assist?
An Expanded Access Programme (EAP) allows patients to access investigational treatments before full regulatory approval. Sciensus helps pharmaceutical companies develop and execute EAPs across Europe, ensuring regulatory compliance, efficient patient access, and seamless distribution.
How does Sciensus ensure regulatory compliance in different European countries?
With in-depth regulatory expertise across multiple European markets, we work closely with local authorities to ensure rare disease drugs meet all necessary approval requirements. Our team stays updated on regulatory changes to streamline the approval process for our partners.
What patient support services does Sciensus provide?
Our Patient Support Programmes (PSP) include multilingual healthcare professional-led interventions, treatment adherence support, real-world data collection, and caregiver assistance. These programmes improve patient outcomes and enhance treatment success.
